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Comparative trial with highly purified natural ACTH,
synthetic ACTH 1—24 peptide and synthetic ACTH 1—39 peptide
By P. J. BROMBACHER, H. J. BUYTENDIJK and F. MAESEN
From the Departments of Clinical Chemistry and Diseases of the Chest, Joseph Hospital, Heerlen, The Netherlands
(Eingegangen am 27. Januar 1969)
The intensity and duration of the adrenocortical stimulation^ produced by highly purified natural porcine ACTH (44 U/m/), synthetic
ACTH 1—24 peptide (0.44 mg tetracosapeptide/m/) and synthetic ACTH 1—39 peptide (0.4 mg l—39 peptide/m/) with all preparations
dissolved in a gelatin solution, \vere investigated in one trial with a total of 18 healthy volunteers.
The activity of synthetic ACTH 1—39 peptide significantly exceeds that of the synthetic 1—24 peptide, but is of shorter duration than
that of the natural peptide.
An insgesamt 18 gesunden Probanden wurden Wirksamkeit und Dauer einer Stimulation der Nebennierenrinde mit natürlichem ACTH
und synthetischen ACTH-Peptiden untersucht. Geprüft wurden hochgereinigtes natürliches ACTH vom Schwein (44 IE/m/),
synthetisches ACTH 1—24 Peptid (0,44 mg = 44 IE/m/) und synthetisches ACTH 1—39 Peptid (0,4 mg = 44 IE/m/), die jeweils in
einer Gelatinelösung gelöst wurden.
Die Aktivität des synthetischen ACTH l—39 Peptides ist signifikant höher als die des l—24 Peptids, aber von kürzerer Dauer als die des
natürlichen Peptids.
During long term treatment of patients with corti-
costeroids many clinicians require a means of reacti-
vating the adrenal cortex which is therapeutically more
or less suppressed. This is notably the case in the
treatment of bronchial asthma, rheumatic disease and
simular affections.
Up till some years ago some more or less highly purified
corticotropin preparations of animal origin were fre-
quently used for the stimulation of the adrenal cortex.
As a matter of fact there was always the danger of
sensitising the patient towards the animal protein with
all the unwanted consequences such as anaphylactic
shock in all its forms. These effects were seen indeed in
about five percent of people repeatedly undergoing
this therapy (1, 2). For those reasons an iatrogenically
inactivated adrenal cortex was often preferred as
presenting a less serious risk than that accompanying
regular administration of non-human protein hor-
mone.
This deadlock was solved by the availability of a
polypeptide with corticotropic activity synthesized by
SCHWYZER and KAPPELER (3). This peptide of fully
synthetic origin did not induce sensibilization which ·
was also demonstrated with skin tests on patients
known to react allergically to animal corticotropin (4).
The non appearance of reactions came up to expecta-
tions because the sequence of the 24 amino acids of the
synthetic product is the same as that in part of the
natural ACTH molecule for many animal species and
man (5). A certain disappointment however was felt
when it became evident that the duration of action of the
synthetic peptide was much shorter than for the natural
hormone. Nevertheless with adequate dosage the effect
was the same for both preparations for some hours
after intravenous or intramuscular administration as
measured by the increase of plasma cortisol levels. As
was expected a very satisfactory effect was seen on
continuous intravenous infusion (6), but there are
practical objections to this.
Consequently a definite want is felt for a synthetic
preparation comparable to natural corticotropin with
respect to duration of action and adrenal cortex sti-
mulatory effect, but without the allergic properties of
the latter.
Possibly the shorter duration of action of the synthetic
24 amino acid peptide could be explained by the ab-
sence of the last part of the natural molecule containing
amino acids number 25 to 39. It could be that this tail
of the molecule offers a certain stereochemical protection
against breakdown viz. inactivation by the human
organism.
In order to obtain more detailed information we per-
formed a comparative investigation with highly puri-
fied porcine corticotropin1), and two synthetic poly-
peptides containing viz. 242) and 393) amino acids. In
order to secure about the same depot properties on
intramuscular administration for the three preparations,
gelatin was added to all peptide solutions, this being a
procedure often used with the natural hormone.
Material und Methods
The investigation was performed with eighteen healthy coope-
rative volunteers, all males between 18 and 26 years old, who
had never previously received either corticosteroids or cortico-
tropin. They stayed in bed during the experiment.
Blood samples were taken at 9 a. m. (time —1 h.), 10 a. m. (0 h.),
14 p. m. (- -4 h.), 16 p. m. (+6 h.), and 18 p. m. (+8 h.).
In this trial the time of injection (10 a. m.) was the same in all
volunteers, the dosage (1 m/) was the same for all types of pre-
parations.
x) Cortrophin, Organon.
2) 1—24 peptide, cortrosyn, Organon.
3) 1—39 peptide (synthetic), Organon.
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The quality of ACTH gelatin preparations is dependent on the
properties of the gelatin used. Therefore one lot of gelatin was
used for manufacturing the three different preparations. The
ACTH 1—39 peptide showed a potency of 110IU/mg in the
subcutaneous ascorbic acid depletion test.
The above mentioned preparations were manufactured in the
following concentrations:
44 U/m/ highly purified natural porcine ACTH
0.44 mg = 44. U/m/synthetic 1—24 peptide
0.4 mg = 44 U/m/ synthetic 1—39 peptide.
The investigation was performed in 6 randomised "blocks", each
block consisting of 3 healthy volunteers in whom the preparation
was tested simultaneously and at any time under equal circum-
stances'.
The ACTH packings to be used for each block were only distin-
guished by random numbers, denoting the order to be observed
in each phase of handling (injecting, sampling of blood) of the
volunteers. The volunteers were assigned to the order numbers
in some convenient way. As a consequence the distribution of
both volunteers and order numbers was random with respect to
the treatment.
The corticotropic effect was evaluated from the plasma cortisol
levels. The plasma corticoid values were determined using the
fluorometric method of MATTINGLY (7).
Initial values were determined one hour before and at the moment
of the intramuscular injection. Blood samples for plasma cortisol
determination were also taken after 4, 6 and 8 hours.
Results
The plasma cortisol values found are given in the
accompanying table 1.
For each observation time after injection a separate
analysis was made for the comparison of the three
treatments. In order to meet at least approximately the
basic requirements for the analyses (uniform scatter and
Gaussian error distribution), all observed values were
replaced by their logarithms.
Each analysis was carried out taking due account of the
subdivision by blocks and of each patient's initial value,
defined as the mean of his —l h and 0 h value. In this
trial, however, the initial values were found to have
exerted no demonstrable influence on the values at
any time after injection, so that finally they were not
accounted for in the comparison among the treat-
ments.
Tab. 1
Plasma corticoid levels after administration of different peptides with
corticotropic activity. Experiment in six randomised blocks
60
Treatment
Volun- Plasma corticoids, ^g/100 ml
teer Block — 1 0 4 6 8 hrs.
Highly p u r i f i e d
natural porcine
ACTH dissolved in
gelatin 44 U/mf
mean
1 — 24 pept ide
dissolved in
gelatin
0,44 mg/m/
mean
1 — 39 pep t ide
dissolved in
gelatin
0,4 mg/mJ
mean
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Fig. 1
Plasma corticoid levels after administration of different peptides with
corticotropic activity. Experiment in six randomised blocks; retrans-
formed means of six healthy volunteers after statistical analysis on the
logarithms of the values. See text
• porcine ACTH Δ—Δ l—39 peptide D—D l—"24 peptide
For each observation time after injection the treatment
means have been retransformed to their antilogarithms
and plotted in the figure 1. The same has been done with
the general mean initial value.
Discussion and conclusions
From the statistical evaluation of the data obtained it
appears that the activity of the 1—39 peptide signi-
ficantly exceeds that of the 1—24 peptide both at
4 h and 6 h. At 8 h there is still a suggestion of a diffe-
rence in the same direction (two sided significance,
level P2 = 0.087). The activity of the 1—39 peptide
does not differ significantly from the natural prepa-
ration at 4 h, but it is significantly lower both at 6 h
and 8 h. The clinical results reveal that from the pre-
parations tested the 1—24 peptide in gelatin is least
active. This is not surprising and is a confirmation of
what we expected. The difference in response of highly
purified natural ACTH and the synthetic 1—39 peptide
is more or less unexpected, since the main constituent
of natural ACTH is the 1—39 peptide. An explanation
for this difference in activity could be the presence of
smaller and higher molecular weight components iri
natural ACTH, which protect the 1—39 peptide from
inactivation by tissue enzymes at the site of injection.
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